A multicenter retrospective study on the real-world outcomes of autologous vs. allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphoma in China.
10.1097/CM9.0000000000001575
- VernacularTitle:A multicenter retrospective study on the real-world outcomes of autologous
vs. allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphoma in China
- Author:
Zhen-Yang GU
1
;
Yu-Jun DONG
2
;
Xiao-Rui FU
3
;
Nai-Nong LI
4
;
Yao LIU
5
;
Xiao-Xiong WU
1
;
Yi-Ni WANG
6
;
Yu-Hang LI
1
;
Han-Yun REN
2
;
Ming-Zhi ZHANG
3
;
Xiao-Fan LI
4
;
Mai-Hong WANG
5
;
Ya-Mei WU
1
;
Dai-Hong LIU
1
;
Zhao WANG
6
;
Liang-Ding HU
1
;
Wen-Rong HUANG
1
Author Information
1. Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100071, China.
2. Department of Hematology, Peking University First Hospital, Beijing 100034, China.
3. Department of Oncology, Zhengzhou University First Affiliated Hospital, Zhengzhou, Henan 450000, China.
4. Department of Hematology, Fujian Institute of Hematology, Fuzhou, Fujian 350000, China.
5. Center of Hematology, Xinqiao Hospital, Army Medical University, Chongqing 400037, China.
6. Department of Hematology, Capital Medical University Affiliated Beijing Friendship Hospital, Beijing 100050, China.
- Publication Type:Multicenter Study
- MeSH:
China;
Hematopoietic Stem Cell Transplantation;
Humans;
Lymphoma, T-Cell, Peripheral/therapy*;
Neoplasm Recurrence, Local;
Retrospective Studies;
Transplantation, Autologous;
Transplantation, Homologous;
Treatment Outcome
- From:
Chinese Medical Journal
2021;134(13):1584-1592
- CountryChina
- Language:English
-
Abstract:
BACKGROUND:There were few studies on real-world data about autologous hematopoietic stem cell transplantation (auto-HSCT) or allogeneic HSCT (allo-HSCT) in peripheral T-cell lymphoma (PTCL). This study aimed to investigate the clinical outcomes of patients who received auto-HSCT or allo-HSCT in China.
METHODS:From July 2007 to June 2017, a total of 128 patients who received auto-HSCT (n = 72) or allo-HSCT (n = 56) at eight medical centers across China were included in this study. We retrospectively collected their demographic and clinical data and compared the clinical outcomes between groups.
RESULTS:Patients receiving allo-HSCT were more likely to be diagnosed with stage III or IV disease (95% vs. 82%, P = 0.027), bone marrow involvement (42% vs. 15%, P = 0.001), chemotherapy-resistant disease (41% vs. 8%, P = 0.001), and progression disease (32% vs. 4%, P < 0.001) at transplantation than those receiving auto-HSCT. With a median follow-up of 30 (2-143) months, 3-year overall survival (OS) and progression-free survival (PFS) in the auto-HSCT group were 70%(48/63) and 59%(42/63), respectively. Three-year OS and PFS for allo-HSCT recipients were 46%(27/54) and 44%(29/54), respectively. There was no difference in relapse rate (34%[17/63] in auto-HSCT vs. 29%[15/54] in allo-HSCT, P = 0.840). Three-year non-relapse mortality rate in auto-HSCT recipients was 6%(4/63) compared with 27%(14/54) for allo-HSCT recipients (P = 0.004). Subanalyses showed that patients with lower prognostic index scores for PTCL (PIT) who received auto-HSCT in an upfront setting had a better outcome than patients with higher PIT scores (3-year OS: 85% vs. 40%, P = 0.003). Patients with complete remission (CR) undergoing auto-HSCT had better survival (3-year OS: 88% vs. 48% in allo-HSCT, P = 0.008). For patients beyond CR, the outcome of patients who received allo-HSCT was similar to that in the atuo-HSCT group (3-year OS: 51% vs. 46%, P = 0.300).
CONCLUSIONS:Our study provided real-world data about auto-HSCT and allo-HSCT in China. Auto-HSCT seemed to be associated with better survival for patients in good condition (lower PIT score and/or better disease control). For patients possessing unfavorable characteristics, the survival of patients receiving allo-HSCT group was similar to that in the auto-HSCT group.
